Children with Down syndrome (DS, trisomy 21) are at increased risk of developing certain cancers. Children with DS have a reported 10-20 fold increased risk of developing acute myeloid leukemia (AML). Anthracycline-based treatment regimens achieve good results in pediatric patients with DS and AML. However, children with AML and DS are at high risk for treatment-related toxicities, including anthracycline-related cardiotoxicity. For example, a report from the Children's Oncology Group documented anthracycline-related cardiomyopathy in 17.5 % of the patients with AML and DS. There is wide inter-individual variability in terms of susceptibility to anthracycline-related cardiotoxicity, and there are no clinical treatments to prevent the development of cardiotoxicity in children with AML and DS. For the past eight years, we have been conducting integrative studies to identify myocardial determinants associated with the pathogenesis of anthracycline cardiotoxicity in individuals with DS. We have shown that the expression of the chromosome 21 gene CBR1 is increased in DS myocardium and results in higher synthesis rates of cardiotoxic anthracycline alcohol metabolites. This is important because anthracycline alcohol metabolites resulting from high CBR1 activity are 40 times more cardiotoxic than parent anthracyclines. These findings have contributed to support the rationale for dose reduction strategies in new clinical protocols implemented by the Children's Oncology Group (trial: AAML0431. Blood, 2017). Novel preliminary data suggest that the expression of DYRK1A, a key chromosome 21 gene associated with various DS phenotypes, is altered in DS myocardium. Our data also suggest that the expressions of 1) embryonic transcript variants of cardiac troponin TNNT2 and 2) the master splicing factor SRp55, are significantly increased in myocardial tissue from individuals with DS. We propose that altered expression of the DYRK1A-SRp55- TNNT2 pathway increases the susceptibility of DS myocardium to the cardiotoxic effects of anthracycline drugs. Studies in Aim 1 will examine the role of the DYRK1A-SRp55-TNNT2 pathway during anthracycline cardiotoxicity in a model of beating cardiomyocytes with trisomy 21. Studies in Aim 2 will examine whether combined pharmacological inhibition of CBR1 and DYRK1A activities protects trisomic cardiomyocytes from the cardiotoxic effects of anticancer anthracyclines. To further investigate determinants for drug induced cardiotoxicity in DS, studies in Aim 3 will define the extent of genome-wide splicing alterations linked to the increased expression of the master splicing factor SRp55 in myocardial tissue from persons with DS. These integrative studies will provide new data for the design of pharmacological interventions to prevent the development of anthracycline cardiotoxicity in pediatric patients with DS and AML.
Children with Down syndrome (DS) and acute myeloid leukemia (AML) are highly susceptible to anthracycline- related cardiotoxicity. This project will delineate the contribution of specific molecular factors to anthracycline- cardiotoxicity in the DS setting. Results of these integrative studies will provide new data for the design of novel pharmacological interventions to prevent the development of cardiotoxicity in children with DS and AML.
